target directory

fms like tyrosine kinase 3 flt3 clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT01468467

Source recordAI-normalized

A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant

AC220 (ASP2689), developed by Daiichi Sankyo, is positioned as a maintenance therapy for patients with Acute Myeloid Leukemia (AML) post-allogeneic hematopoietic stem cell transplant. The market for AML therapies is growing, driven by increasing incidence rates and the need for improved post-transplant management options. The competitive landscape includes other FLT3 inhibitors, such as quizartinib, which may pose a challenge. Successful outcomes from this trial could enhance Daiichi Sankyo's portfolio in hematologic malignancies and provide a strategic advantage in the post-transplant AML treatment space. Diligence should focus on the safety profile and potential market access strategies, considering the evolving regulatory environment for oncology therapies.

AI analysis

Indication: Leukemia, Myeloid, Acute

Modality: small molecule

Target: FMS-like tyrosine kinase 3 (FLT3)

Sponsor: Daiichi Sankyo

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 10, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: FMS-like tyrosine kinase 3 (FLT3)

View original source fields

Condition raw: Leukemia, Myeloid, Acute

Condition normalized: Leukemia, Myeloid, Acute

Modality raw: small molecule

Modality normalized: small molecule

Target raw: FMS-like tyrosine kinase 3 (FLT3)

Target normalized: FMS-like tyrosine kinase 3 (FLT3)

Open report

NCT04788420

Source recordAI-normalized

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With FLT3-ITD Positive Acute Myeloid Leukemia

The study investigates the efficacy of sorafenib maintenance therapy in patients with FLT3-ITD positive acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given the prevalence of FLT3-ITD mutations in AML and the associated poor prognosis, successful outcomes from this study could enhance the therapeutic positioning of sorafenib in the AML treatment landscape. The results may influence treatment guidelines and could lead to increased market share for sorafenib, particularly in the context of maintenance therapies. Additionally, the collaboration with multiple prestigious hospitals enhances credibility and may facilitate broader acceptance and adoption of findings within clinical practice. The competitive landscape includes other FLT3 inhibitors, and the study's findings could provide a comparative advantage for sorafenib if superior outcomes are demonstrated.